Clinical Trial Update: U.S. FDA Places Hold on VYNE’s VYN202 Phase 1b Trial in PsO
The FDA has verbally informed VYNE Therapeutics Inc. that it placed a clinical hold on its Phase 1b study evaluating VYN202 for the treatment of moderate-to-severe plaque psoriasis.